Names of protocol contributors/authors |
5a |
5 (8.1%) |
7 (15.2%) |
12 (11.1%) |
Name and contact details of sponsor |
5b |
31 (50.0%) |
31 (67.4%) |
62 (57.4%) |
Research question described and justified |
6a |
35 (56.5%) |
13 (28.3%) |
48 (44.4%) |
Countries where data will be collected listed |
9 |
9 (14.5%) |
36 (78.3%) |
45 (41.7%) |
Eligibility criteria for study centres and who will perform the intervention |
10 |
8 (12.9%) |
24 (52.2%) |
32 (29.6%) |
Sample size: assumed values for outcome |
14 |
41 (36.9%) |
20 (43.5%) |
61 (56.5%) |
Location of participant recruitment |
15 |
7 (11.3%) |
36 (78.3%) |
43 (39.8%) |
Person(s) who will recruit participants |
15 |
5 (8.1%) |
31 (61.4%) |
36 (33.3%) |
Expected recruitment rate |
15 |
20 (32.3%) |
25 (45.4%) |
45 (41.7%) |
Person who will enrol/assign participants |
16c |
12 (19.4%) |
17 (37.0%) |
29 (26.7%) |
Personnel who will collect data |
18a |
19 (30.7%) |
24 (52.2%) |
43 (39.8%) |
Strategies to promote participant retention and complete follow-up |
18b |
38 (61.3%) |
16 (34.8%) |
54 (50.0%) |
DMC is planned or why it is not planned |
21a |
41 (66.1%) |
22 (47.8%) |
63 (58.3%) |
Audits/external monitoring described |
23 |
26 (41.9%) |
3 (5.5%) |
29 (26.9%) |
Who will have access to full dataset |
29 |
18 (29.0%) |
7 (15.2%) |
25 (23.2%) |
Plans to disseminate trial results to key stakeholders/publication provided |
31a |
29 (46.8%) |
31 (67.4%) |
60 (55.6%) |
Authorship eligibility criteria |
31b |
23 (37.1%) |
15 (32.6%) |
38 (35.2%) |
Plans for granting access to full trial protocol |
31c |
6 (9.7%) |
2 (4.4%) |
8 (7.4%) |